Granules India has received an approval of further investment of $17.07 million by way of debt/equity in Granules Pharmaceutical Inc., a wholly owned foreign subsidiary of the company. The board of directors at its meeting held on April 28, 2016 has approved for the same.
The board has also approved further investment of Rs 50 crore by way of debt/equity in GIL Lifescienses, a wholly owned Indian subsidiary.
Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
